Lupin Launches Lotemax Generic

  Published 10 months ago

Lupin launches Loteprednol Etabonate Ophthalmic Suspension, a generic equivalent of Lotemax, targeting $55 million U.S. market.

  • Drug treats steroid-responsive eye inflammations and post-surgery swelling, matching Lotemax’s therapeutic efficacy.
  • Lotemax posted $55 million U.S. sales in May 2025, per IQVIA data; Lupin aims to capture share.
  • Mumbai-based Lupin distributes across 100+ markets, focusing on complex generics, APIs, and biotech solutions.

You might like these

Indian Metal Stocks Surge on Weak Dollar, Copper Gains

India GST Cuts Taxes, Sparks Growth

Quess Corp Reports Q4 Loss: Stock Dips

Mahanagar Gas Outperforms Peers Amid Bullish Outlook

Brigade Plans Fundraise via NCDs

Adani Ports Stock Falls Amid Middle East Tensions

IT, Nestle Drag Nifty, Sensex Down

News that matters the most ⚡